NEW YORK, May 6, 2020 /PRNewswire/ -- AIkido Pharma
Inc. (Nasdaq: AIKI) today announced execution of an Artificial
Intelligence (AI), and Machine Learning (ML) research agreement
with Cogia Biotech LTD ("Cogia") (www.cogia.de) to accelerate the
Company's pancreatic cancer genetic marker research. Cogia is
a Big-data, AI, and ML software company committed to using powerful
AI engines and algorithms to develop compelling outcomes in drug
development. Cogia provides state-of-the-art digital
information and discovery tools to subject-matter experts and
scientists working in genetics and cancer research, to advance drug
development. Cogia's existing clients include many
international companies, including international pharmaceutical
companies.
Cogia will augment the Company's efforts of using machine
learning to find genetic markers that could lead to pancreatic
cancer. As with many cancers, early detection is vital, but in
pancreatic cancer, surgical intervention is currently the only
effective treatment for the extension of life. Pancreatic cancer is
relatively rare; however, it is the third leading cause of cancer
deaths in the United States. The disease is often
asymptomatic, making early detection and treatment difficult or
even impossible. Only 20% of individuals are diagnosed with
pancreatic cancer early enough to be surgical candidates. Reliable
markers for early detection will expand the number of patients who
are eligible for life-extending surgery.
Andreas Typaldos, Executive
Chairman of Cogia Biotech, expressed his excitement about the
research agreement with AIkido. "Even during the preparatory work
leading up to this strategic agreement with AIkido, one could see
the promise of compelling outcomes in early and better detection of
pancreatic cancer and possibility for novel and more effective
therapeutics using state-of-the-art technologies like AI and ML.
The very earliest project-design work sessions between Cogia
Biotech AI/ML data scientists, bio-informatics engineers, and
cancer research scientists, on one hand, and AIkido and
University of Texas Southwestern Medical
Center research scientists, on the other, clearly pointed to
how compelling and appropriate is the vision of Anthony Hayes for having AIkido use of these
breakthrough biotech technologies in disease detection and drug
development. We are excited and honored to be part of Anthony's
plan and effort."
Anthony Hayes, CEO of AIkido
stated, "We have completed several significant capital raises and
are now putting that capital to work with the aim of
achieving asymmetric rewards for our shareholders. As part of our
goal to increase our use of AI and ML in drug development, our new
research agreement with Cogia augments our pancreatic cancer
research project with the University of
Texas Southwestern Medical Center. Cogia has
significant depth and skill, as demonstrated by their notable
client base. We believe that Cogia can help us use machine
learning to develop panels of markers to rapidly identify patients
who have initiated early events in pancreatic cancer. Moreover, it
is the goal of the machine learning protocols to identify which
individuals are at risk for slow or rapid progression of the
disease and catalyze the development of better early detection
methods. It is our objective that the machine learning approach
will help identify drugs best suited for potentially lifesaving
individual patient treatment. We are proud to partner with
Cogia on this project."
About AIkido
AIkido was initially formed in 1967 and is a biotechnology
company with a diverse portfolio of small-molecule anti-cancer
therapeutics. The Company's platform consists of patented
technology from leading universities and researchers and we are
currently in the process of developing an innovative therapeutic
drug platform through strong partnerships with world renowned
educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of
therapeutics includes therapies for pancreatic cancer, acute
myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In
addition, we are constantly seeking to grow our pipeline to treat
unmet medical needs in oncology
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its business contained therein. Thus, actual
results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Contact:
|
|
Investor
Relations:
|
Hayden IR
|
|
Brett Maas, Managing
Partner
|
|
Phone: (646)
536-7331
|
|
Email:
brett@haydenir.com
|
|
www.haydenir.com
|
|
|
AIkido:
|
Phone:
212-745-1373
|
|
Email:
investorrelations@AIkido.com
|
|
www.AIkido.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-executes-artificial-intelligence-and-machine-learning-research-agreement-with-cogia-biotech-ltd-301054142.html
SOURCE AIkido Pharma Inc.